Cross Contamination GAP Assessment: A GMP Guide

About This White Paper

This guide is based on Rephine’s white paper, Is Your Shared Facility Defensible? A Risk Based Approach to Cross Contamination Control. It sets out why traditional cleaning based justifications are no longer sufficient on their own, what a thorough Cross Contamination GAP Assessment should cover, and the ten step checklist we recommend for evaluating your contamination control strategy.

The full white paper includes a detailed breakdown of the eight key assessment areas, a gap classification model for prioritising findings, and practical guidance on what a defensible contamination control strategy looks like in practice. You can download the complete PDF at the end of this article.

What’s Changing?

Regulatory expectations around cross contamination have shifted. Where cleaning validation alone once felt sufficient, manufacturers are now expected to demonstrate a broader, science and risk based contamination control strategy.

You may recognise some of the criteria your site has relied on historically:

• 10 ppm limits
• 1/1000th of the minimum therapeutic dose
• Visual cleanliness checks
• Campaign production schedules
• General cleaning validation practices

These tools can still be useful in specific contexts, but on their own they no longer provide a universal justification for manufacturing different products in shared facilities.

Why has this happened?

Current GMP expectations require manufacturers to evaluate the real risk of unwanted transfer of products, active substances, residues, impurities or microbiological agents. This evaluation must consider toxicological and pharmacological properties, route of administration, patient population, process characteristics, equipment design, cleanability and potential contamination pathways, specific to each operation rather than generic industry assumptions.

Three developments have driven this shift:

• EMA guidance on Health Based Exposure Limits (HBELs) introduced a stronger expectation for toxicologically justified limits, commonly expressed as Permitted Daily Exposure (PDE) values.
• ICH Q9(R1) provides the broader Quality Risk Management (QRM) framework, requiring risk based decisions to be scientifically justified, documented and proportionate to the level of risk.
• EU GMP Volume 4 Part I Chapter 3 and Chapter 5, Annex 15 and Volume 4 Part II reinforce the need for risk based qualification, validation and cleaning validation across both finished product and API manufacturing. Annex 1 may also apply where sterile manufacturing or microbiological contamination control falls within scope.

In this context, a Cross Contamination GAP Assessment is how you determine whether your current contamination control strategy is complete, current, risk based and defensible during a regulatory inspection.

Why It Matters for Your Business

Cross contamination remains one of the most significant GMP risks in pharmaceutical manufacturing. It can compromise product quality, patient safety and your standing with regulators, often without any visible warning sign on the shop floor.

This matters most if your site falls into any of the following categories:

• Multiproduct facilities sharing equipment across products
• Campaign manufacturing operations
• Outsourced or contract manufacturing activities
• Legacy installations not originally designed for the current product portfolio
• New plant projects still in the design or qualification stage
• Complex, multi site supply chains

What happens if you do not act?

Without a structured, evidence based assessment, gaps tend to surface in one of three ways: as inspection findings, as quality events, or as business disruptions. All three are more costly, and more disruptive, to address reactively than to identify proactively.

A Cross Contamination GAP Assessment helps you avoid that position. It gives you a structured way to identify critical risk points, evaluate the controls you already have, and define the actions needed to close any gaps. It supports Quality Assurance, Production, Engineering, Validation, Regulatory Affairs, Toxicology, Qualified Persons, Marketing Authorisation Holders and Contract Manufacturing Organisation teams in understanding exactly where risk exposure sits and what to prioritise first.

Take Action Now

A defensible contamination control strategy is built, not inherited. Historical cleaning validation or legacy facility design does not remain valid indefinitely simply because it once passed an inspection.

The most valuable Cross Contamination GAP Assessments are evidence based and linked to real manufacturing practice. They challenge legacy assumptions, verify whether controls are genuinely effective, and ensure that any risk acceptance is scientifically justified, not simply inherited from previous years.

Rephine supports API manufacturers, pharmaceutical and biotechnology companies in evaluating, strengthening and defending their cross contamination control strategies. Our support covers GMP audits, Cross Contamination GAP Assessments, shared facility risk assessments, cleaning validation strategy reviews, HBEL/PDE implementation support, validation lifecycle assessments, CAPA planning and inspection readiness, shaped around where your site actually is today.

By working with Rephine, you gain an independent view of your contamination control maturity, surface hidden compliance risks early, and walk away with clear, risk based actions to build a stronger and more defensible quality system.

Download the full white paper to get the complete ten step assessment checklist, the gap classification model and detailed guidance on building a defensible contamination control strategy.